NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Both Neurocrine Biosciences NBIX and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on specialty medicines and treatments for serious health conditions.

NBIX focuses on neuroscience, with growth primarily led by its flagship drug Ingrezza. In contrast, TEVA operates as a global pharmaceutical giant that develops, manufactures and markets both branded and generic/biosimilar drugs.

But which one makes for a better investment pick today? Let's examine the fundamentals of the two stocks to make a prudent choice.

The Case for NBIX

This San Diego-based company’s commercial portfolio currently includes three first-in-class therapies. Neurocrine’s top-line growth is benefiting from strong uptake of Ingrezza, the blockbuster VMAT2 inhibitor approved for two indications — tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). The drug remains the company’s primary revenue driver and a key pillar of its growth story.

Ingrezza sales rose 17% year over year to $1.4 billion in the first half of 2026, supported by record new prescriptions and double-digit total volume growth. The strong performance prompted management to raise its full-year 2026 Ingrezza sales guidance to $2.83-$2.88 billion from $2.7-$2.8 billion. The midpoint implies approximately 13% year-over-year growth, indicating that Neurocrine expects the drug's commercial momentum to remain solid through the remainder of the year.

The company is also diversifying its revenue base beyond Ingrezza. Crenessity, launched in December 2024 for classic congenital adrenal hyperplasia (CAH), is emerging as a meaningful second growth driver. The drug generated $337 million in sales in the first half of 2026, up about 400% year over year and already exceeding its full-year 2025 sales of $301 million.

The company further expanded its rare-disease portfolio through the $2.9 billion acquisition of Soleno Therapeutics, completed in May 2026. The acquisition added Vykat XR, which is approved to treat hyperphagia in Prader-Willi syndrome (PWS). Following the acquisition, Neurocrine recorded $54 million from the drug’s sales in the second quarter of 2026.

Beyond its marketed products, Neurocrine has a broad pipeline. Its late-stage pipeline includes phase III programs for osavampator in major depressive disorder and direclidine in schizophrenia. The company also has several earlier-stage programs targeting areas including obesity, classic CAH and movement disorders. NBIX expects around 10 clinical study readouts next year.

However, Ingrezza remains a major source of revenues, leaving Neurocrine exposed to competitive pressures. Teva's Austedo and Austedo XR compete directly with Ingrezza in TD and HD chorea. In addition, pricing pressure could increase as a lower negotiated Medicare price for Austedo takes effect in 2027.

Neurocrine is also facing execution risks with Vykat XR, which remains in the early stages of commercialization. Post-marketing serious adverse events have been reported to the FDA, although such reports do not establish that the drug caused the events. NBIX acknowledges that adverse-event or safety concerns could affect market acceptance, prompt regulatory scrutiny or increase treatment discontinuations.

The Case for TEVA

The Israel-based company is one of the world’s largest generic drugmakers in terms of both total and new prescriptions. It enjoys a leading position in the United States, where it commands a share of more than 6% of total U.S. generic prescriptions.

Teva is gradually moving from predominantly traditional small-molecule generic manufacturer to a more diversified player in complex generics and biosimilars. In the past few quarters, the company has launched several successful biosimilars and other high-value complex generics. These include Truxima (biosimilar to Roche’s Rituxan), Simlandi (biosimilar to AbbVie’s Humira), Selarsdi (biosimilar to J&J’s Stelara), Epysqli (biosimilar to AstraZeneca’s Soliris) and Novo Nordisk’s Victoza.

Teva also maintains a diversified portfolio of higher-margin branded and innovative medicines, which are transforming its portfolio mix and financial profile. Its newer products — Austedo, Ajovy (preventive treatment of migraine) and Uzedy (schizophrenia) — are gaining market share and delivering strong top-line growth.

Austedo remains the largest contributor to the franchise, with global sales rising 40% year over year to $696 million in the second quarter. Teva expects Austedo revenues of $2.45-$2.60 billion in 2026. The Austedo franchise got a boost from the launch of Austedo XR, a new once-daily formulation of Austedo. Teva expects Austedo revenues to exceed $3 billion by 2030.

Ajovy is also delivering strong growth, with global revenues increasing 56% year over year to $244 million in the second quarter. Teva expects Ajovy sales of $850-$870 million in 2026 and estimates peak global sales potential of approximately $1 billion. Meanwhile, Uzedy revenues increased 43% to $77 million in the second quarter, with full-year 2026 sales expected to reach $270-$290 million.

However, Teva’s generics business faces a revenue cliff for lenalidomide capsules (the generic version of Bristol-Myers’ Revlimid), due to increased competition in the United States. Global generics revenues are expected to be flat to down in the low single digits in local currency in 2026, excluding the impact of generic Revlimid and the Japan business divestment. This outlook reflects fewer high-value launches, lower seasonal demand for OTC products and increased competition in some markets. The generic market is also highly crowded, as Teva competes with players like Dr. Reddy’s RDY, Viatris and Sandoz, among others.

The company also faces competitive pressure for some of its key branded drugs. Austedo competes with Ingrezza, while Ajovy faces competition from other CGRP-targeting therapies, including Amgen's Aimovig and Eli Lilly's LLY Emgality.

In addition, Teva has a high debt load – the company’s consolidated debt (short- plus long-term) was approximately $16.6 billion at the end of June 2026.

How Do Estimates Compare for NBIX & TEVA?

The Zacks Consensus Estimate for Neurocrine’s 2026 sales and EPS implies year-over-year growth of 31% and 27%, respectively. Bottom-line estimates for 2026 have declined during the past 30 days.

Image Source: Zacks Investment Research

For Teva, the Zacks Consensus Estimate for 2026 sales is expected to decline 4% year over year, while EPS estimates are expected to fall 6%. Bottom-line estimates for 2026 have been trending downwards over the past 30 days.

Image Source: Zacks Investment Research

Price Performance and Valuation of NBIX & TEVA

Year to date, shares of Neurocrine have risen 8%, while those of TEVA have increased 18%. In comparison, the industry has climbed 2%, as seen in the chart below.

Image Source: Zacks Investment Research

From a valuation standpoint, NBIX seems to be trading at a premium compared to TEVA, going by the price/earnings (P/E) ratio. Neurocrine’s shares currently trade at 17.61 times forward 12-month earnings, higher than 13.91 for Teva.

Image Source: Zacks Investment Research

NBIX or TEVA: Which Is a Better Pick?

Both Neurocrine and Teva offer investors exposure to growing neuroscience markets and both have important commercial products that could support future growth. However, NBIX appears to be the better pick at present.

Neurocrine offers a stronger near-term growth trajectory, supported by continued Ingrezza momentum, the rapid growth of Crenessity and the addition of Vykat XR. The company also has a broader pipeline, with multiple potential clinical readouts expected in 2027, providing several catalysts that could support the stock’s performance.

In comparison, Teva’s innovative medicines, particularly Austedo, Ajovy and Uzedy, are delivering strong growth. However, weakness in its generics business remains a near-term headwind, while the company’s high debt load adds to its financial risk. These factors could limit the upside potential of the stock despite the strength of its newer branded medicines.

NBIX carries a Zacks Rank #3 (Hold), while TEVA has a Zacks Rank #4 (Sell). This further reinforces NBIX’s more favorable standing in the current investment landscape.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research